Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2025-12-26 @ 11:13 PM
Study NCT ID:
NCT06692712
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-11-18
First Post:
2024-11-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase 3, Open-label Study to Assess the Efficacy and Safety of a Single Lumbar Intrathecal Administration of MELPIDA in Individuals with Hereditary Spastic Paraplegia Type 50 (SPG50) Versus Matched Prospective Concurrent Controls.
Sponsor:
Elpida Therapeutics SPC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-03-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2032-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-11-14
First Submit QC Date:
None
Study First Post Date:
2024-11-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-14
Last Update Post Date:
2024-11-18
Last Update Post Date Type:
ACTUAL